Theriva Biologics, Inc.
TOVX
$0.25
$0.014.52%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 52.73% | 55.12% | 43.55% | -57.02% | 16.28% |
| Total Depreciation and Amortization | -7.69% | 0.00% | -15.15% | -28.95% | -33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.33% | 159.59% | -84.69% | 134.99% | -168.02% |
| Change in Net Operating Assets | -11.72% | -200.19% | -307.91% | -169.93% | -14,400.00% |
| Cash from Operations | 48.36% | 38.56% | -10.38% | -36.50% | 2.56% |
| Capital Expenditure | -- | -- | -- | -1,500.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -1,500.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 12.50% | -- | -- | 83.58% | -- |
| Issuance of Common Stock | -- | 149,842.86% | -92.49% | 263.80% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.66% | -- | -- | -- | -- |
| Cash from Financing | 25.85% | 120,728.57% | -103.98% | 284.15% | -- |
| Foreign Exchange rate Adjustments | -138.71% | 60.98% | -723.53% | -358.33% | 344.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.36% | 215.00% | -2,451.11% | 223.02% | 67.66% |